ES2156731B1 - Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano. - Google Patents

Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.

Info

Publication number
ES2156731B1
ES2156731B1 ES009901175A ES9901175A ES2156731B1 ES 2156731 B1 ES2156731 B1 ES 2156731B1 ES 009901175 A ES009901175 A ES 009901175A ES 9901175 A ES9901175 A ES 9901175A ES 2156731 B1 ES2156731 B1 ES 2156731B1
Authority
ES
Spain
Prior art keywords
preparation
tranexamic acid
fibrinogen composition
human fibrinogen
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009901175A
Other languages
English (en)
Other versions
ES2156731A1 (es
Inventor
Debart Pere Ristol
Camison M Isabel Bravo
Rodriguez Jesus Fernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols SA
Original Assignee
Grifols SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols SA filed Critical Grifols SA
Priority to ES009901175A priority Critical patent/ES2156731B1/es
Priority to ARP000102221A priority patent/AR024551A1/es
Priority to HU0001841A priority patent/HUP0001841A2/hu
Priority to UY26146A priority patent/UY26146A1/es
Priority to SK758-2000A priority patent/SK7582000A3/sk
Priority to EP00500101A priority patent/EP1057490A3/en
Priority to JP2000159727A priority patent/JP2001019644A/ja
Publication of ES2156731A1 publication Critical patent/ES2156731A1/es
Application granted granted Critical
Publication of ES2156731B1 publication Critical patent/ES2156731B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a una utilización del ácido tranexámico para la preparación de una composición de fibrinógeno humano obtenido a partir de plasma humano o mediante métodos de tecnología recombinante o transgénica, con la adición simultánea de albúmina humana, para acortar el tiempo de solubilización al añadir un disolvente fisiológicamente compatible y a la composición de fibrinógeno.
ES009901175A 1999-05-31 1999-05-31 Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano. Expired - Fee Related ES2156731B1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ES009901175A ES2156731B1 (es) 1999-05-31 1999-05-31 Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.
ARP000102221A AR024551A1 (es) 1999-05-31 2000-05-09 Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano
HU0001841A HUP0001841A2 (en) 1999-05-31 2000-05-10 Use of tranexamic acid for the preparation of a human fibrinogen composition
UY26146A UY26146A1 (es) 1999-05-31 2000-05-16 Utilización de ácidos tranexamico para la preparación de una composición de fibrinógeno humano ley 17.164
SK758-2000A SK7582000A3 (en) 1999-05-31 2000-05-19 Use of tranexamic acid for the preparation of a human fibrinogen composition
EP00500101A EP1057490A3 (en) 1999-05-31 2000-05-25 Use of tranexamic acid for the preparation of a human fibrinogen composition
JP2000159727A JP2001019644A (ja) 1999-05-31 2000-05-30 ヒトフィブリノゲン組成物の製剤用のトラネキサム酸の使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009901175A ES2156731B1 (es) 1999-05-31 1999-05-31 Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.

Publications (2)

Publication Number Publication Date
ES2156731A1 ES2156731A1 (es) 2001-07-01
ES2156731B1 true ES2156731B1 (es) 2002-02-16

Family

ID=8308626

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009901175A Expired - Fee Related ES2156731B1 (es) 1999-05-31 1999-05-31 Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.

Country Status (7)

Country Link
EP (1) EP1057490A3 (es)
JP (1) JP2001019644A (es)
AR (1) AR024551A1 (es)
ES (1) ES2156731B1 (es)
HU (1) HUP0001841A2 (es)
SK (1) SK7582000A3 (es)
UY (1) UY26146A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2214967B1 (es) 2003-03-06 2005-06-16 Probitas Pharma, S.A Procedimiento para la eliminacion de virus en soluciones de fibrinogeno y fibrinogeno obtenido por dicho procedimiento.
RU2484817C1 (ru) * 2012-03-11 2013-06-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО АГМА Минздравсоцразвития России) Способ профилактики повышенной кровопотери и коагулопатического кровотечения при вагинальном родоразрешении в раннем послеродовом периоде
EP2695605B1 (en) * 2012-08-07 2017-05-03 Parapharm Development Ltd. Tranexamic acid composition
KR101841587B1 (ko) * 2016-01-12 2018-05-14 주식회사 녹십자홀딩스 피브리노겐의 정제방법
CA3073685A1 (en) 2017-08-27 2019-03-07 Anti-Viral Technologies, Llc Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101811B (en) * 1981-06-30 1985-01-03 Racal Dana Instr Ltd Improvements in and relating to the screening of electrical circuit arrangements
DE3203775A1 (de) * 1982-02-04 1983-08-11 Behringwerke Ag, 3550 Marburg Fibrinogenzubereitung, verfahen zu ihrer herstellungund ihre verwendung
JPH08512215A (ja) * 1993-03-30 1996-12-24 オパーバス・ホールディング・ビー・ブイ 二成分フィブリングルー
GB9424732D0 (en) * 1994-12-08 1995-02-08 Common Services Agency Heat treated blood plasma proteins
EP0856317A1 (en) * 1997-01-31 1998-08-05 Omrix Biopharmaceuticals S.A. A stabilized mixture comprising fibrinogen
AU8336098A (en) * 1997-06-05 1998-12-21 Omrix Biopharmaceuticals S.A. Fibrinogen concentrate from human plasma

Also Published As

Publication number Publication date
ES2156731A1 (es) 2001-07-01
EP1057490A2 (en) 2000-12-06
UY26146A1 (es) 2000-12-29
AR024551A1 (es) 2002-10-16
HUP0001841A2 (en) 2002-09-28
SK7582000A3 (en) 2001-05-10
JP2001019644A (ja) 2001-01-23
EP1057490A3 (en) 2002-04-03
HU0001841D0 (en) 2000-07-28

Similar Documents

Publication Publication Date Title
ECSP034430A (es) Esteres oxigenados de acidos 4-yodo fenilamino benzhidroxamcios
BR0016879A (pt) Métodos para transferência de interleucina-2 por via pulmonar
BRPI0409133B8 (pt) preparações farmacêuticas estavéis compreendendo metilnaltrexona
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
DK1307227T3 (da) Farmaceutiske sammensætninger
NO20010062D0 (no) Bifenylsulfonamider som duale angiotensin-endotelin- reseptorantagonister
CY1110602T1 (el) Φαρμακευτικες συνθεσεις υπο μορφη γελης ή διαλυματος με βαση τη διυδροτεστοστερονη, μεθοδοι παρασκευης και χρησεις τους
CY1116103T1 (el) Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης
DE60037450D1 (de) Funf-helix protein
EA200300937A1 (ru) Оральная фармацевтическая композиция цефподоксима проксетила
GT200000190A (es) Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas-4-carboxiamino-2-sustituidas.
CY1105721T1 (el) Δερματικοι αναισθητικοι παραγοντες
CY1109843T1 (el) Αναλογα της βιταμινης d
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
EP1423137A4 (en) STEREO-ISOMERS OF LIPOPEPTIDE, METHODS OF PREPARATION AND USEFUL INTERMEDIATES
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
WO2005066207A8 (en) Glucagon-like peptide-1 analogs with long duration of action
ATE211391T1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
ES2156642T3 (es) Composicion que comprende un derivado de acido cinamico y un polimero poliaminado.
ES2158034T3 (es) Derivado de benzotiepina opticamente activo, su preparacion y uso.
ECSP045110A (es) Composiciones de la preparación que contiene un compuesto fisiologicamente activo de acidos inestables y procesos para su producción
ES2156731B1 (es) Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano.
DK1240326T3 (da) Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor
CY1105165T1 (el) Φαρμακευτικη συνθεση που πepιλαμβανει συνδυασμο μετφορμινης και 4-οξοβουτανικου οξεος και η χρηση αυτης για τη θepαπεια του διαβητη
BR0016638B1 (pt) compostos anÁlogos de homopiperidilbenzimidazàis substituÍdos como relaxantes féndicos, processo para preparar os mesmos, composiÇço farmacÊutica e processo para preparÁ-la.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20010701

Kind code of ref document: A1

Effective date: 20010701

FD2A Announcement of lapse in spain

Effective date: 20190926